Minerva Neurosciences Exercises Right To Opt Out Of Agreement With Janssen For Seltorexant

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced that it has exercised its right to opt out of its agreement with Janssen Pharmaceutica NV (Janssen) for the future development of seltorexant (MIN-202). As a result, Minerva will now collect a royalty on worldwide sales of seltorexant in all indications in the mid-single digits, with no financial obligations to Janssen.

According to Remy Luthringer, Ph.D., executive chairman and chief executive officer of Minerva, opting out at the current stage of development will be more valuable . . .